GT Biopharma Reports $2.8 Million Net Loss in Q1 2026, Zero Revenue

GT Biopharma, Inc. has reported its financial results for the first quarter of 2026, revealing a net loss of approximately $2.8 million, a significant increase from the $776,000 loss recorded in the same period of 2025. The company's revenues remained at zero, consistent with the previous year, as it continues to focus on the development of its immuno-oncology products without any approved product candidates for sale. Operating expenses for the quarter totaled $2.8 million, up 47% from $1.9 million in the prior year, primarily driven by a substantial increase in selling, general, and administrative expenses, which rose by 188% to $2.4 million.

In terms of financial position, GT Biopharma reported total assets of $9.996 million as of March 31, 2026, an increase from $8.106 million at the end of 2025. The company's cash and cash equivalents rose to $8.923 million, up from $6.811 million, reflecting a net increase of $2.112 million during the quarter. Current liabilities also saw a slight increase to $2.416 million from $2.319 million, resulting in total stockholders' equity of $7.580 million, compared to $5.787 million at the end of the previous fiscal year.

Strategically, the company has made notable advancements in its product pipeline, particularly with its TriKE® technology. GT Biopharma has initiated clinical trials for its next-generation product candidates, GTB-3650 and GTB-5550, with the latter having dosed its first patient in May 2026. The company is also actively engaged in collaborations, including a sponsored research agreement with the University of Minnesota, aimed at further developing its TriKE® platform. Additionally, GT Biopharma has successfully raised capital through the issuance of Series L Preferred Stock and warrants, generating approximately $4.6 million in financing during the quarter.

Despite these developments, the company faces ongoing challenges, including substantial doubt about its ability to continue as a going concern, as highlighted in its financial statements. The company has not generated revenue from product sales and has incurred operating losses since its inception. Management has indicated that it will need to secure additional financing to sustain operations, as existing cash resources may not be sufficient to fund anticipated levels of operations over the next year. The company is actively monitoring its compliance with Nasdaq listing requirements, particularly regarding its stock price, which has implications for its ability to raise capital in the future.